Page 222

49. Schmidt WK. 1998. Overview of current investigational drugs for the treatment of chronic pain. National Managed Health Care Congress, Second Annual Conference on Therapeutic Developments in Chronic Pain. Annapolis, MD, May 18, 1998.

50. Shapiro RS. 1994. Legal bases for the control of analgesic drugs. Journal of Pain and Symptom Managemnent 9:153-159.

51. Shen M, Piser TM, Seybold VS, Thayer SA. 1996. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. Journal of Neroscience 16:4322-4334.

52. Shohami E, Weidenfeld J, Ovadia H, Vogel Z, Hanus L, Fride E, Breuer A, Ben-Shabat S, Sheskin T, Mechoulam R. 1996. Endogenous and synthetic cannabinoids: Recent advances. CNS Drtug Reviews 2:429-451.

53. Spilker B. 1989. Multinational Drug Companies: Issues in Drug Discovertl and Developmnent. New York: Raven Press.

54. Standaert DG, Young AB. 1996. Treatment of central nervous system degenerative disorders. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RR, Gilman AG, Editors, Goodmnan & Gilman's: The Pharinacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill. Pp. 503-519.

55. Striem S, Bar-Joseph A, Berkovitch Y, Biegon A. 1997. Interaction of dexanabinol (HU211), a novel NMDA receptor antagonist, with the dopaminergic system. European lournlal of Pharmacology 388:205-213.

56. Timpone JG, Wright DJ, Li N, Egorin MJ, Enama ME, Mayers J, Galetto G, DATRI 004 Study Group. 1997. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRI 004 study group. AIDS Researchi andl HwumanR Retroviruses 13:305315.

57. Turk DC, Brody MC, Akiko OE. 1994. Physicians' attitudes and practices regarding the long-term prescribing of opioids for non-cancer pain. Pain 59:201-208.

58. Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ. 1997. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry 12:913-919.

59. Voth EA, Schwartz RH. 1997. Medicinal applications of delta-9-tetrahydrocannabinol and marijuana. Annals of Internal Medicine 126:791-798.

60. Wall ME, Sadler BM, Brine D, Taylor H, Perez-Reyes M. 1983. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clinical Phartmacology and Therapeutics 34:352-363.

61. Zurier RB, Rossetti RG, Lane JH, Goldberg JM, Hunter SA, Burstein SH. 1998. Dimethylheptyl-THC-11 oic acid: A non-psychoactive antiinflammatory agent with a cannabinoid template structure. Arthritis and Rlheumatism 41:163-170.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement